The University of Rochester Medical Center in New York will host a 10th Lupus Education Day on Saturday, Oct. 15, providing a forum for people with systemic lupus erythematosus (SLE) and their caregivers to interact and to better understand the latest developments in treating and managing the disease. “This is a great opportunity…
News
Large-scale analysis of genome-wide gene expression signatures allows researchers to discriminate between patients with active and inactive systemic lupus erythematosus — and could help physicians in adjusting treatment to control disease activity while minimizing the risk of side effects. The study reporting the method, “Clinical Application of a Modular…
The Lupus Research Alliance, together with the John and Marcia Goldman Foundation, funded a study that led to researchers identifying some 150 medications, approved by the U.S. Food and Drug Administration (FDA) for other diseases, that could be promising treatments for systemic lupus erythematosus (SLE). The study, published in the journal…
Patients with systemic lupus erythematosus (SLE) may be at increased risk of incident respiratory failure, according to a nationwide study by Taiwanese researchers. The study, “Effect of Systemic Lupus Erythematosus on the Risk of Incident Respiratory Failure: A National Cohort Study,” published in the journal PLoS One, also…
GlaxoSmithKline (GSK) announced that it has filed applications with U.S. and European regulatory agencies to extend the approval of Benlysta (belimumab) as a treatment for active, autoantibody-positive systemic lupus erythematosus (SLE) to its newer, subcutaneous formulation. The applications draw on positive results from a Phase 3 study in SLE patients treated by injection with the…
Aurinia Pharmaceuticals recently announced that it will host a lupus nephritis (LN) expert breakfast on Friday, Sept. 30, from in New York, to present recently released results from the AURA-LV trial in patients with active LN. The Phase 2b clinical trial (NCT02141672) is a randomized, controlled double-blind study comparing…
A case study found that epilepsy and rapid cognitive decline in an 70-year-old man initially masked — and complicated — diagnosing his central nervous system (CNS) lupus, but once the disease was identified and treated with immunotherapy, his neurological symptoms considerably improved. The study, “Neuropsychiatric Systemic Lupus Erythematosus: A Diagnostic Conundrum,” published…
Researchers at the biotechnology company Shade have developed a sensor, going under the same name, that allows people with systemic lupus erythematosus to accurately measure their ultraviolet (UV) exposure, enabling them to find and adjust to the personal exposure threshold that triggers their symptoms. While many wearable devices claim to measure vital signs, Shade —…
In a letter to the editor of the journal Nefrologia, a recent case report focused on a single patient with a diagnosis of simultaneous systemic lupus erythematosus (SLE) and Gaucher disease (GD), two unrelated medical conditions. The study, “Gaucher disease and Lupus: A rare association?” aims to present and…
The presence of anti-ficolin 3 antibodies could be used as a biomarker to diagnose active lupus with kidney involvement according to a study published in the scientific journal Plos One.
Recent Posts
- AMETHYST trial of litifilimab making “strong progress,” Biogen says
- What reasonable workplace accommodations actually look like
- How to mitigate the sense of failure that can arise during a lupus flare
- What to remember if you’re dating with a chronic illness
- Finding our superpower by surviving lupus flares